1044.7500 1.15 (0.11%)
NSE Sep 12, 2025 15:31 PM
Volume: 559.9K
 

1044.75
0.11%
HDFC Securities
With a revised TP of 495 (24x on FY20E EPS), we maintain BUY. Cadila (CDH) continues to be at pace with double-digit YoY growth which started in 2QFY18. In 1QFY19, CDH reported revenue at Rs 28.9bn showing a growth of 32%YoY. EBITDA at Rs 6.4bn and PAT at Rs 4.6bn were up 133% and 233% YoY respectively. EBITDA margin came in at 22.3%, improving ~1000bpsYoY. This growth was primarily driven by the US and India businesses which were up 27% and 40% YoY respectively. Other major segments including LATAM and ROW markets and consumer wellness, animal health, and API businesses also saw double digit growth.
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended